Please login to the form below

Not currently logged in
Email:
Password:

ImmuneXcite boosts senior leadership

Eric Furfine, Ann DeWitt, Jim Geraghty and John Edwards join the firm

ImmuneXcite Eric FurfineImmuneXcite, a US biopharmaceutical firm, has made five appointments to its senior leadership team, four of which are new additions to its board of directors.

Eric Furfine (pictured right) has been appointed as chief scientific officer, acting chief executive officer and a member of the board.

He brings over 25 years of drug industry experience to the leadership team, specialising in driving developments in infectious disease, inflammation and oncology therapeutic areas.

Before joining ImmuneXcite, Furfine served as president of research and development at Eleven Biotherapeutics from 2011 to 2013 and was the senior vice president for research and preclinical development at Adnexus Therapeutics - a Bristol-Myers Squibb research and development company - for four years prior.

Furfine said: “Being part of a company that is leading what we expect to be the next major wave in immune-oncology is an exciting proposition.

“I look forward to working with the ImmuneXcite team to build on a number of years of excellent science.”

Ann DeWitt, Jim Geraghty and John Edwards also join the ImmuneXcite board, with Edwards serving as executive chairman.

Edwards is currently executive chairman at F-star, having previously served as its chief executive officer, and brings over 30 years of biotechnology expertise from Adnexus Therapeutics, Genetics Institute/Wyeth and Genzyme.

DeWitt is senior director of investments at Sanofi-Genzyme BioVentures and brings business leadership experience from Springboard Enterprises, Permeon Biologics and Flagship Ventures.

Geraghty has 30 years of strategic and leadership experience and is currently an entrepreneur-in-residence at Third Rock Ventures, a biotech venture and company-formation fund. He is chairman of the board of Idera Pharmaceuticals and Juniper Pharmaceuticals and has previously worked at Sanofi-Aventis and Genzyme.

Finally, ImmuneXcite's scientific co-founder Ifat Rubin-Bejerano has been named as head of research.

The inventor of the company's technology platform, Rubin-Bejerano also brings 15 years of research experience to the role from Whitehead Institute where she was most recently a senior researcher.

Edwards said: “It is a privilege to collaborate with such an experienced group of colleagues in a thrilling area of drug development with the potential to make a significant shift in the treatment of cancer.”

4th April 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics